Introduction {#sec1}
============

Colorectal cancer (CRC) is one of the most common preventable malignancies worldwide. According to Globocan 2012, it is the third most common cancer in men and second most common in women \[[@cit0001]\]. The highest rates are in developed nations and the lowest rates are presumed to be in Africa, except South Africa \[[@cit0001]\]. The age-standardized incidence rate in West Africa is 4.1/100,000; East Africa 6.5/100,000; Northern Africa 7.1/100,000; Southern Africa 10.9/100,000; South Africa 11.9/100,000; Mauritius 18.6/100,000; United States 25/100,000 and United Kingdom 30.2/100,000 \[[@cit0001]\]. The current colorectal cancer incidence and prevalence data from Africa are presumed to be an underestimate of disease burden. This underestimation is most likely related to data collecting methods, lack of centralized systems, limited knowledge amongst healthcare providers and patient-related factors such as late presentation. As noted, the highest rates of colorectal cancer within the African continent are in Southern Africa, which is where majority of the CRC African data originates (55 percent) \[[@cit0002]\]. Data suggests an overall decline of colorectal cancer, however an increase incidence in individuals younger than 50 years \[[@cit0003]\] and younger African Americans \[[@cit0004]\]. (11.9%) compared to whites (6.7%) \[[@cit0005]\] Zambia is a landlocked country in Southern Africa with a population of approximately 14 million. Colorectal cancer is the 6th most common cancer in Zambia, with an incidence rate of 4.8/100,000 \[[@cit0001]\], prevalence 3/100,000 and mortality rate of 3.8/100,000 \[[@cit0001]\]. GLOBOCAN data is obtained primarily from country cancer registries, which they acknowledge is not comprehensive, thus the true incidence and prevalence of colorectal cancer within the African continent is very uncertain. Further concerns about data validity include late patient presentation to health care providers and limited diagnostic capabilities and resources. With this in mind, we sought to analyze the current colorectal cancer database at the largest national cancer disease hospital in Zambia. We aimed to evaluate the trends of CRC in a native African population based on age at diagnosis, gender and stage at presentation.

Methods {#sec2}
=======

We conducted a retrospective analysis using the CDH database for CRC. CDH is the largest cancer hospital in the capital City (Lusaka) of Zambia and serves as the national referral center. CDH uses Microsoft access as its database, with data manually entered by an analyst. We identified all patients with colorectal cancer from inception of the CDH in 2006 until 2015. The following terminology was entered into the CDH access database to identify patients with CRC: "colon cancer" "rectal cancer" "colorectal cancer" "sigmoid cancer" "recto sigmoid cancer" "ascending colon cancer" "descending colon cancer." We extracted the age, sex, race (white, black, other), year of colorectal cancer diagnosis and mortality. A data collection tool and master sheet code created a priori were used. Patient medical record numbers (MRN) identified in the registry were used to manually locate patient records. These records were manually reviewed by authors (AWA, LB) and the following was extracted: demographics (age, sex, race, place of residence and marital status), clinical presentation, date of diagnosis, mode of diagnosis, stage at diagnosis, treatment outcome and co-morbidity (HIV, Diabetes Mellitus, hypertension) and social (alcohol consumption, smoking). The AJCC (American Joint Committee on Cancer) guidelines were referenced for staging as follows \[[@cit0006]\]: stage 0 - carcinoma in situ/intramucosal carcinoma (involves lamina propria with no extension through the muscularis mucosa), stage 1- carcinoma involves the submucosa (through the muscularis mucosa but not into the muscularis propria) and without nodal involvement, stage 2 - carcinoma involves muscularis propria into or through the serosa, without nodal involvement, stage 3 - carcinoma into submucosa or through serosa with nodal involvement but no distant metastasis, stage 4: carcinoma with or without serosal involvement, with or without nodal involvement, with distant metastasis. Data was analyzed using SAS v9 (SAS Institute Inc., Cary, NC, USA). Descriptive statistics in the form of frequency distributions or sample means (age, BMI) and standard deviations as well as Spearman correlations for year/stage and year/age were found. Year and gender were compared using a test for trend. A p-value of less than 0.05 was used as level of significance. The study was approved by the institutional review board (IRB) at the University Of Missouri School Of Medicine and the Biomedical Research Ethics Committee of the University of Zambia School Of Medicine, Lusaka, Zambia.

Results {#sec3}
=======

A total of 377 medical records were identified in the CDH database between 2007 and 2015, 33 charts could not be manually located, 110 excluded due to duplication (77) or non-CRC diagnosis (33), 234 were included in the final analysis. The mean age of diagnosis was 48.6 years and 62% are males ([Table 1](#t0001){ref-type="table"}). The age at diagnosis ranges from 11-82 years with a median of 50 years and a mean of 48.6 years ([Figure 1](#f0001){ref-type="fig"}). Geographic location, defined as place of residence was identified in 229 (97.8%) CDH medical records. Geographically, 111 (48%) subjects resided in Lusaka and 1 (0.4%) outside of Zambia ([Table 1](#t0001){ref-type="table"}). Co-morbidity and social factors were analyzed ([Table 2](#t0002){ref-type="table"}), however meaningful conclusions could not be made due to significant missing information. The most common clinical presentation was hematochezia 88/213 (41.3%), followed by abdominal pain (59, 27.6%) and intestinal obstruction (56, 26.2%) ([Table 3](#t0003){ref-type="table"}). The most common mode of diagnosis was surgical in 195 subjects (84%), followed by endoscopy (34, 14%) and imaging (4, 2%) ([Table 4](#t0004){ref-type="table"}). The most common histology was adenocarcinoma in 225 (96.5%), most common location was rectum 124 (53%) followed by sigmoid 31 (13.4%) and cecum 26 (11%) ([Table 4](#t0004){ref-type="table"}). Advanced disease (stage 4) at presentation was diagnosed 122 subjects (54%), followed by stage 3 (79, 35%), Stage 2 (19, 8%) and Stage 1 (1, 0.44%) ([Table 5](#t0005){ref-type="table"}). Surgical management was the most common mode of treatment (26.6%) ([Table 5](#t0005){ref-type="table"}). There was no statistically significant difference between both genders in location of tumour (p = 0.52) and stage at presentation (p = 0.27) ([Table 6](#t0006){ref-type="table"}). A trend test shows no difference across years relative to the proportions of male/female (p = 0.56). Using the Spearman Rank correlation, we see no association between year and Stage at diagnosis (p = 0.30) or year and age at presentation (p=0.92).

###### 

Baseline characteristics of the CDH Native African population

                       N             Frequency (%)   Missing
  -------------------- ------------- --------------- ---------
  **Sex**              234                           0
  Male                 144           62              
  Female               90            38              
  **Mean Age (SD)**    48.5 (16.7)                   
  **Marital Status**   231                           3
  Single               37            16              
  Married              166           72              
  Widowed              21            9               
  divorced             7             3               
  **Residence**        229                           5
  Lusaka               111           48              
  Central              20            8.7             
  Copperbelt           45            19.6            
  Northern             6             2.6             
  Luapula              3             1.3             
  Muchinga             4             1.75            
  Eastern              11            4.8             
  Northwestern         3             1.3             
  Western              5             2.1             
  Southern             20            8.7             
  Out of country       1             0.4             

###### 

Social factors, co-morbidity and BMI in CDH population

                            N            \%      Missing
  ------------------------- ------------ ------- ---------
  **Smoking**                                    147
  No                        78           89.66   
  Yes                       9            10.34   
  **Alcohol Consumption**                        155
  No                        62           78.48   
  Yes                       17           21.52   
  **Family History**                             168
  No                        61           92.42   
  Yes                       5            7.58    
  **History of HTN**                             156
  No                        61           78.21   
  Yes                       17           21.79   
  **History of DM**                              161
  No                        66           90.41   
  Yes                       7            9.59    
  **HIV Status**                                 163
  No                        49           69      
  Yes                       22           31      
  **Mean BMI (SD)**         21.3 (5.1)           

CDH: Cancer Disease Hospital; BMI: Body Mass Index; HTN: Hypertension; DM: Diabetes Mellitus; HIV: Human Immunodeficiency Virus

###### 

Clinical presentation at time of diagnosis in CDH population

                                      N     \%     Missing
  ----------------------------------- ----- ------ ---------
  **Clinical Features**               213          21
  Hematochezia                        88    41.3   
  Abdominal pain                      59    27.6   
  Intestinal Obstruction              56    26.2   
  Constipation                        38    17.8   
  Rectal/anal pain                    27    12.6   
  Weight Loss                         26    12.2   
  Mass: anal/perianal/lower abdomen   11    5.1    
  Abdominal Distension                12    5.6    
  Diarrhea                            11    5.1    
  Vomiting                            7     3.2    
  Change in BMs                       7     3.2    
  Pain with BM                        6     2.8    
  Anal discharge                      6     2.8    
  Anemia                              6     2.8    
  Loss of Appetite                    2     0.9    
  Backache                            2     0.94   
  Melena                              2     0.94   
  Appendicitis                        1     0.46   
  Perforation                         1     0.46   
  Urinary incontinence                1     0.46   
  Anal ulcer                          1     0.46   
  Fatigue                             1     0.46   
  tenesmus                            1     0.46   

\*The total adds to more than 100% since subjects may have presented with multiple features

###### 

Clinic pathologic features

                          N         \%      Missing
  ----------------------- --------- ------- ---------
  **Mode of diagnosis**   **232**           2
  Imaging                 4         2       
  Surgical                195       84      
  Endoscopy               34        14      
  **Histopathology**                        1
  Adenocarcinoma          225       96.57   
  Sarcoma                 3         1.29    
  Carcinoid               2         0.86    
  lymphoma                3         1.29    
  **TUMOUR SITE**                           3
  Cecum                   26        11      
  Ascending colon         13        5.6     
  Hepatic flexure         3         1.29    
  Transverse colon        12        5.1     
  Splenic flexure         5         2.16    
  Descending colon        10        4.3     
  Sigmoid                 31        13.4    
  Rectum                  124       53.6    
  Rectosigmoid            12        5       
  Right                   2         0.86    
  left                    1         0.43    

###### 

Stage and treatment of CDH population

                                   N     \%      Missing
  -------------------------------- ----- ------- ---------
  **Stage**                                      9
  Stage IA/IB                      1     0.44    
  Stage IIA/B                      19    8.44    
  Stage III                        79    35.11   
  Stage IV                         122   54.22   
  Not applicable                   4     1.78    
  **Treatment**                    229           5
  None                             16    6.9     
  Surgery                          61    26.6    
  Chemo-radiotherapy               23    10      
  Palliative Radiotherapy          8     3       
  Palliative Chemotherapy          14    6.1     
  Chemotherapy                     6     0.4     
  Chemotherapy and surgery         53    23.1    
  Chemo-radiotherapy and Surgery   34    14.8    
  Palliative Surgery               4     1.7     
  Palliative Chemo-radiotherapy    29    12.6    
  Radiotherapy                     5     0.02    

###### 

Gender differences in tumor location and stage at diagnosis

                       Male         Female       P
  -------------------- ------------ ------------ ------
  **Tumor Location**   **N (%)**    **N (%)**    0.52
  Cecum                17 (11.97)   9 (10)       
  Ascending Colon      9 (6)        3 (3)        
  Hepatic Flexure      1 (.7)       2 (2)        
  Transverse colon     10 (7)       2 (2)        
  Splenic Flexure      4 (3)        1 (1)        
  Descending Colon     6 (4)        4 (5)        
  Sigmoid Colon        16 (11)      11 (12)      
  Rectum               70 (49)      52 (58)      
  Rectosigmoid         7 (5)        4 (5)        
  Right Colon          2 (1)        0            
  Left Colon           0            1 (1)        
  **Stage**                                      0.27
  I (A/B)              0            1 (1.15)     
  II (A/B)             13 (9.7)     6 (6.9)      
  III                  43 (32)      36 (41.38)   
  IV                   78 (58.21)   44 (50.57)   

![Age distribution of colorectal cancer in the CDH population](PAMJ-30-248-g001){#f0001}

Discussion {#sec4}
==========

There is limited data regarding colorectal cancer in Zambia and sub-Saharan Africa. Our study is the first to evaluate the colorectal cancer trends, age of presentation and stage of diagnosis using Cancer Disease Hospital database. In a review of endoscopic and gastrointestinal pathology at a tertiary center in Zambia, Kelly et al identified 57 percent of colorectal cancer in individuals less than 45 years, higher than in the USA or UK, for reasons that were unclear \[[@cit0007]\]. Zyaambo and colleagues reviewed the distribution of cancers between 1990 and 2009, in Zambia, using the Zambian National Cancer registry \[[@cit0008]\]. Data in this cancer registry are collected from district hospitals (total number) using a standard cancer notification form \[[@cit0008]\]. They recognized the challenges of this database that result in incomplete or lower reported data. These challenges are attributed to logistical issues such as lack of an adequate postal service or transportation \[[@cit0008]\]. A rising trend in the incidence of colorectal cancer was noted in a retrospective analysis of colorectal cancer in the department of surgery at the University Teaching Hospital (UTH) in Zambia, comparing the years 1995-1996 to 2003-2004 \[[@cit0009]\]. In another year-long study, a single endoscopist\'s data of 85 patients revealed 28 percent with colorectal cancer and an age distribution between 14 years and 70 years \[[@cit0009]\]. Anecdotally, the Cancer Disease Hospital (CDH) in Zambia most commonly diagnoses patients with colorectal cancer between the age of 25 and 45 years. Understanding the basis for this age difference may reveal important clues to the etiopathogenesis of colorectal cancer in the Zambian population.

Our study provides evidence for younger age presentation of colorectal cancer and later stage of diagnosis at time of presentation. Our data also shows predominantly left sided (rectal cancer) in the native African population, which is different from the occurrence in African Americans who predominantly present with right-sided (proximal) colon cancer \[[@cit0004]\]. The right side predominance 60% versus 6% left sided has also been reported in Nigeria, West Africa, which is different from our study, however as in Zambia, the Nigerian population had a late stage at presentation and an increased incidence in the younger population, mean age 57 years \[[@cit0010]\]. In another study, Veruttipong et al compared the Egyptian population based cancer registry to the SEER database and found the incidence of colorectal cancer higher in the Egyptian population under the age of 40 years compared to the USA SEER population and predominant rectal lesion presentation similar to our Zambian CDH data \[[@cit0011]\]. This propensity for colorectal cancer in younger African population and left side predominance has also been supported in a South African population that compared within the different ethnic groups, revealing younger presentation in blacks (50 years) compared to whites (64 years) and Indians (60 years) and the most common cancer location is left sided (sigmoid and rectum) \[[@cit0012]\]. Limitations of our study are missing information in the co-morbidity and social factors limit interpretation, however highlights the importance of obtaining and recording a detailed medical history. The referral biases limit extrapolation to a general population-the increase number of cases noted in the capital city may have to do more with proximity to the Cancer Disease Hospital. The strengths of this study are that this is the first detailed analysis of colorectal cancer cases at CDH and in Zambia. Secondly the data contributes towards database strengthening, development of screening policies and serves as a platform for future research exploring risk factors.

Conclusion {#sec5}
==========

In conclusion, CRC accounts for a significant socioeconomic burden, mortality and morbidity hence it is important to raise awareness and implement preventative measures. Our study provides some baseline information for further studies evaluating risk factors and understanding of the development of colorectal cancer. To our knowledge, there are currently no colorectal cancer screening programs in most African countries. In a 2008 survey by the International Colorectal cancer screening network (ICRCSN) that included 35 programs from 24 countries, none were from the African continent \[[@cit0013]\]. Our research provides valuable data to understand the distribution of colorectal cancer and the development of policy in management and applicable screening guidelines.

What is known about this topic {#sec5.1}
------------------------------

-   There are racial differences in the occurrence of colorectal cancer;

-   There is a trend for colorectal cancer occurrence in the younger age group;

-   Colorectal cancer is preventable, yet most cases present at a later stage in Sub-Saharan African population compared to the Western world.

What this study adds {#sec5.2}
--------------------

-   Our study suggests a late stage of colorectal cancer presentation in this population; there are currently no published colorectal cancer screening guidelines in Zambia, and to the best of our knowledge in Africa; colorectal cancer screening is an integral component to prevention, early detection and management to improve clinical outcomes hence our data supports exploring policy to develop colorectal screening guidelines;

-   Our data shows an earlier age of presentation of colorectal cancer and importance for further research to understand this trend;

-   Hematochezia is the most common clinical presentation hence further research exploring the use of screening tools such as the fecal occult blood test (FOBT) or the fecal immunochemical test (FIT) is warranted in this population.
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